EGFR and pancreatic neoplasm: Finally, we confirmed that the inhibition of EGFR by erlotinib significantly sensitizes pancreatic cancer cells to AZD8055 in vivo and in vitro, which might suggest a novel strategy for pancreatic cancer therapy.